Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 7/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.38 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384235 | 1.00 | SYK (0.45) | SYKCTSLRENCTSSCA12 | |
| SCHEMBL3384237 | 1.00 | SYK (0.45) | SYKCTSLRENCTSSCA12 | |
| SCHEMBL3382125 | 0.89 | MEN1 (0.47) | CTSLRENCTSSKMT2APSMB1 | |
| SCHEMBL3382121 | 0.89 | MEN1 (0.47) | CTSLRENCTSSKMT2APSMB1 | |
| SCHEMBL3382127 | 0.89 | MEN1 (0.47) | CTSLRENCTSSKMT2APSMB1 | |
| SCHEMBL3379673 | 0.88 | MEN1 (0.46) | KMT2A | |
| SCHEMBL3379680 | 0.88 | MEN1 (0.46) | KMT2A | |
| SCHEMBL3379676 | 0.88 | MEN1 (0.46) | KMT2A | |
| SCHEMBL3627659 | 0.87 | ACACB (0.40) | BCHE | |
| SCHEMBL3627651 | 0.87 | ACACB (0.40) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828974-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8183231-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-1765850-B1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMA INC (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7687540-B2 | Substituted propane phosphinic acid esters | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1851234-B1 | SUBSTITUTED PROPANE PHOSPHINIC ACID ESTERS | AVENTIS PHARMA INC (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20070270385-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID ESTERS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-22 | — | — | US | disclosed |
| EP-1851234-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID ESTERS | Aventis Pharmaceuticals, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1765850-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | Aventis Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| WO-2006086734-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID ESTERS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2005118618-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270385-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID ESTERS | PHOSPHO1, PTEN, GRIA1 | SYK 3093/4885CTSL 3098/4885REN 1164/4885 |
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | SYK 3688/4885CTSL 3298/4885REN 1110/4885 |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | SYK 3688/4885CTSL 3298/4885REN 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.